Table 1

Baseline Characteristics of the Study Population

All Patients (n = 145)Hp 1-1 or 2-1 (n = 77)Hp 2-2 (n = 68)p Value
Demographic characteristics
 Age, yrs62.2 ± 10.363 ± 10.761 ± 9.80.331
 Male114 (78.6)58 (75)56 (82)0.30
 Body mass index, kg/m226.1 ± 3.625.7 ± 3.126.6 ± 3.90.167
Cardiovascular risk factors
 Hypertension69 (47.6)33 (42.9)36 (52.9)0.225
 Current or previous smoking82 (56.6)46 (59.7)36 (52.9)0.410
 Hyperlipidemia51 (35.2)25 (32.5)26 (38.2)0.468
 Diabetes23 (15.9)12 (15.6)11 (16.2)0.922
 Family history of CAD30 (20.7)11 (14.3)19 (27.9)0.043
Medication before hospital admission
 Beta-blockers31 (21.4)16 (20.8)15 (22.1)0.851
 ACE-I/ARB50 (34.5)22 (28.6)28 (41.2)0.111
 Diuretic agent7 (4.8)6 (7.8)1 (1.5)0.08
 Ca-blockers11 (7.6)7 (9.1)4 (5.9)0.466
 Antithrombotic agents41 (28.3)16 (20.8)25 (36.8)0.033
 Anticoagulant agents4 (2.8)3 (3.9)1 (1.5)0.374
 Nitrates3 (2.1)2 (2.6)1 (1.5)0.634
 Statins28 (19.3)9 (11.7)19 (27.9)0.013
 Amiodarone0 (80.0)0 (0)0 (0)
 Propafenone1 (0.7)0 (0)1 (1.5)0.286
 Flecainide0 (0)0 (0)0 (0)
 Sotalol2 (1.4)2 (2.6)0 (0)0.181
Killip class0.075
 I135 (93.1)69 (89.6)66 (97.0)
 II1 (0.7)1 (1.3)0 (0.0)
 III1 (0.7)0 (0.0)1 (1.5)
 IV8 (5.5)7 (9.1)1 (1.5)
Site of myocardial infarction
 Anterior myocardial infarction61 (42.1)30 (39)31 (45.6)0.420
 Nonanterior myocardial infarction84 (57.9)46 (61)37 (54.4)
Myocardial enzymes
 Peak Troponin I, ng/dl29.1 (14.5–65.8)25.8 (11.2–57.8)33.1 (19.1–80.9)0.134
Time to pPCI, h2.5 (1.5–5.0)2.0 (1.5–4.0)3.0 (1.4–5.1)0.308
TIMI flow-grade pre-PCI0.672
 093 (64.1)93 (64.1)44 (64.7)
 138 (26.2)38 (26.2)13 (19.1)
 29 (6.2)9 (6.2)7 (10.3)
 35 (3.4)5 (3.4)4 (5.9)
TIMI flow-grade post-PCI0.040
 02 (1.4)1 (1.3)1 (1.5)
 14 (2.8)1 (1.3)3 (4.4)
 211 (7.6)3 (3.9)8 (11.8)
 3128 (88.3)72 (93.5)56 (82.4)
GRACE-risk score (% risk)3.4 ± 5.64.2 ± 7.42.4 ± 1.70.06

Continuous variables are expressed as mean ± SD or median (confidence interval), discrete variables are expressed as n (%). Bold values indicate significant differences among groups.

ACE-I = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; CAD = coronary artery disease; GRACE = global registry of acute coronary events; LAD = left anterior descending coronary artery; LCX = left circumflex coronary artery; MACE = major adverse cardiac events; pPCI = primary percutaneous coronary intervention; RCA = right coronary artery; TIMI = thrombolysis in myocardial infarction.